Approved Equity Investment for Establishing a New Manufacturing Facility in Angola
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivanta Industries' board approved acquiring a 35% equity stake in Angola-based Angav Indústria Farmacêutica S.A. as part of a partnership to sell pharmaceutical products internationally. The company also approved the sale of ~6.25 Bigha of freehold land in Sanand, Ahmedabad (no impact on operations), and appointed new Internal and Secretarial Auditors, while the Company Secretary Ms. Vinita Keswani resigned effective May 6, 2025. On the financial side, consolidated FY25 revenue surged to Rs. 10,980.34 lakhs (vs Rs. 3,723.86 lakhs in FY24, ~195% growth), largely driven by its newly acquired subsidiary Trinity Ganesh Pvt Ltd. However, the company swung to a consolidated loss of Rs. 132.22 lakhs (vs Rs. 92.50 lakh profit in FY24), with cost of materials consumed jumping to Rs. 8,570.44 lakhs. Standalone revenue declined to Rs. 2,285.31 lakhs with a loss of Rs. 119.58 lakhs. Trade receivables and payables both ballooned sharply, borrowings rose to Rs. 2,186 lakhs, and operating cash flow remained negative at Rs. (538.29) lakhs.
The Angola entry signals international pharma ambitions but execution risk is high given the company has just turned loss-making with negative operating cash flows and rising debt. Shareholders should watch for due diligence outcomes, the impact of the land sale on liquidity, and whether the subsidiary-driven revenue growth can be converted into profitability in FY26.